Efficacy and Prognostic Factors of Stereotactic Body Radiotherapy Combined with Immunotherapy for Pulmonary Oligometastases: a Preliminary Retrospective Cohort Study

Overview

Journal Transl Lung Cancer Res

Date 2024 Sep 12

PMID 39263027

Authors

Mei-Na Piao

Jing Xie

Min-Min Jin

Xiao-Ting Ma

Zheng Dou

Jian-Ping Wang

Jin-Li Li

Affiliations

Soon will be listed here.

Abstract

Background: Stereotactic body radiotherapy (SBRT) combined immunotherapy has a synergistic effect on patients with stage IV tumors. However, the efficacy and prognostic factors analysis of SBRT combined immunotherapy for patients with pulmonary oligometastases have rarely been reported in the studies. The purpose of this study is to explore the efficacy and prognostic factors analysis of SBRT combined immunotherapy for patients with oligometastatic lung tumors.

Methods: A retrospective analysis was conducted on 43 patients with advanced tumors who received SBRT combined with immunotherapy for pulmonary oligometastases from October 2018 to October 2021. Local control (LC), progression-free survival (PFS), and overall survival (OS) were assessed using the Kaplan-Meier method. Univariate and multivariate analyses of OS were performed using the Cox regression model, and the P value <0.05 was considered statistically significant. The receiver operating characteristic (ROC) curve of neutrophil-to-lymphocyte ratio (NLR) after SBRT was generated. Spearman correlation analysis was used to determine the relationship of planning target volume (PTV) with absolute lymphocyte count (ALC) before and after SBRT and with neutrophil count (NE) after SBRT. Additionally, linear regression was used to examine the relationship between ALC after SBRT and clinical factors.

Results: A total of 43 patients with pulmonary oligometastases receiving SBRT combined with immunotherapy were included in the study. The change in NLR after SBRT was statistically significant (P<0.001). At 1 and 2 years, respectively, the LC rates were 90.3% and 87.5%, the OS rates were 83.46% and 60.99%, and the PFS rates were 69.92% and 54.25%, with a median PFS of 27.00 (17.84-36.13) months. Univariate and multivariate Cox regression analyses showed that a shorter interval between radiotherapy and immunization [≤21 days; hazard ratio (HR) =1.10, 95% confidence interval (CI): 0.06-0.89; P=0.02] and a low NLR after SBRT (HR =0.24, 95% CI: 1.01-1.9; P=0.03) were associated with improved OS. The ROC curve identified 4.12 as the cutoff value for predicting OS based on NLR after SBRT. NLR after SBRT ≤4.12 significantly extended OS compared to NLR after SBRT >4.12 (log-rank P=0.001). Spearman correlation analysis and linear regression analysis showed that PTV was negatively correlated with ALC after SBRT.

Conclusions: Our preliminary research shows that SBRT combined with immunotherapy has a good effect, and NLR after SBRT is a poor prognostic factor for OS. Larger PTV volume is associated with decreased ALC after SBRT.

Citing Articles

The optimal stereotactic body radiotherapy dose with immunotherapy for pulmonary oligometastases: a retrospective cohort study.

Qian X, Fang Z, Jiang W, Chou J, Lu Y, Jabbour S J Thorac Dis. 2024; 16(10):7072-7085.

PMID: 39552865 PMC: 11565358. DOI: 10.21037/jtd-24-1624.

References

Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael R . Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014; 89(5):1084-1091. DOI: 10.1016/j.ijrobp.2014.04.025. View

Ashrafizadeh M, Farhood B, Musa A, Taeb S, Rezaeyan A, Najafi M . Abscopal effect in radioimmunotherapy. Int Immunopharmacol. 2020; 85:106663. DOI: 10.1016/j.intimp.2020.106663. View

Zhang H, Lin J, Huang Y, Chen Y . The Systemic Immune-Inflammation Index as an Independent Predictor of Survival in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Radiotherapy. J Inflamm Res. 2024; 17:4575-4586. PMC: 11249110. DOI: 10.2147/JIR.S463163. View

Hellman S, Weichselbaum R . Oligometastases. J Clin Oncol. 1995; 13(1):8-10. DOI: 10.1200/JCO.1995.13.1.8. View

Aarts C, Hiemstra I, Beguin E, Hoogendijk A, Bouchmal S, Van Houdt M . Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair. Blood Adv. 2019; 3(22):3562-3574. PMC: 6880908. DOI: 10.1182/bloodadvances.2019031609. View

Zou W, Chen L . Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8(6):467-77. DOI: 10.1038/nri2326. View

Bauml J, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T . Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. JAMA Oncol. 2019; 5(9):1283-1290. PMC: 6624820. DOI: 10.1001/jamaoncol.2019.1449. View

Xiang Y, Zhang N, Lei H, Wu J, Wang W, Zhang H . Neutrophil-to-lymphocyte ratio is a negative prognostic biomarker for luminal A breast cancer. Gland Surg. 2023; 12(3):415-425. PMC: 10086769. DOI: 10.21037/gs-23-80. View

Klement R, Hoerner-Rieber J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J . Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiother Oncol. 2018; 127(2):246-252. DOI: 10.1016/j.radonc.2018.02.016. View

10.

Tree A, Khoo V, Eeles R, Ahmed M, Dearnaley D, Hawkins M . Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013; 14(1):e28-37. DOI: 10.1016/S1470-2045(12)70510-7. View

11.

Goto W, Kashiwagi S, Asano Y, Takada K, Takahashi K, Hatano T . Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. BMC Cancer. 2018; 18(1):1137. PMC: 6245848. DOI: 10.1186/s12885-018-5051-9. View

12.

Chen D, Verma V, Patel R, Barsoumian H, Cortez M, Welsh J . Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. Int J Radiat Oncol Biol Phys. 2020; 108(1):196-203. DOI: 10.1016/j.ijrobp.2020.01.032. View

13.

Cao Y, Chen H, Sahgal A, Erler D, Badellino S, Biswas T . The impact of local control on widespread progression and survival in oligometastasis-directed SBRT: Results from a large international database. Radiother Oncol. 2023; 186:109769. DOI: 10.1016/j.radonc.2023.109769. View

14.

Park Y, Chang A . Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy. Korean J Gastroenterol. 2022; 79(6):252-259. DOI: 10.4166/kjg.2022.021. View

15.

Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I . Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009; 27(20):3290-6. DOI: 10.1200/JCO.2008.21.5681. View

16.

Yang R, Sun L, Li C, Wang Y, Yao J, Li H . Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021; 12(1):832. PMC: 7864927. DOI: 10.1038/s41467-021-21099-2. View

17.

Turchan W, Chmura S . The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review. Ann Palliat Med. 2021; 10(5):6028-6044. DOI: 10.21037/apm-20-1528. View

18.

Izmailov T, Ryzhkin S, Borshchev G, Boichuk S . Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials. Cancers (Basel). 2023; 15(21). PMC: 10648904. DOI: 10.3390/cancers15215234. View

19.

Mayinger M, Kotecha R, Sahgal A, Kim M, Lo S, Louie A . Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines. Lung Cancer. 2023; 182:107284. DOI: 10.1016/j.lungcan.2023.107284. View

20.

Upadhyay R, Venkatesulu B, Giridhar P, Kim B, Sharma A, Elghazawy H . Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis. Radiother Oncol. 2021; 157:225-233. DOI: 10.1016/j.radonc.2021.01.034. View